The 10 most recent market catalysts affecting $QTTB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34
Morgan Stanley analyst Judah Frommer has initiated coverage on Q32 Bio (QTTB) with an 'Overweight' rating and a price target of $34. This is a significant event for Q32 Bio as it m…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Q32 Bio, Raises Price Target to $36
HC Wainwright & Co. analyst Joseph Pantginis has maintained a 'Buy' rating on Q32 Bio (QTTB) and substantially raised the price target from $13 to $36. This significant increase in…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 75
Why Is Q32 Bio Stock Falling Wednesday?
Q32 Bio priced a public offering of common stock and pre-funded warrants, aiming to raise $200 million. While the proceeds are earmarked for crucial research and clinical developme…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 75
Q32 Bio Launches $200M Public Offering Of Its Common Stock
Q32 Bio is conducting a significant public offering to raise $200 million, with an additional $30 million option for underwriters. This move, while providing crucial capital for cl…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Upgrades Q32 Bio to Overweight, Announces $66 Price Target
Wells Fargo analyst Derek Archila upgraded Q32 Bio (QTTB) from Equal-Weight to Overweight and announced a $66 price target. This upgrade reflects a more optimistic outlook from a p…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Oppenheimer Maintains Outperform on Q32 Bio, Raises Price Target to $40
Oppenheimer analyst Jay Olson has raised the price target for Q32 Bio (QTTB) from $20 to $40, while maintaining an Outperform rating. This substantial increase in the price target,…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 85
Q32 Bio Announces 36-Week Topline Results From Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA
Q32 Bio reported positive 36-week topline results for its lead candidate, bempikibart, in a Phase 2a trial for alopecia areata. The drug demonstrated clinically meaningful efficacy…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
The primary event disclosed is Q32 Bio's upcoming announcement of 36-week topline results from its SIGNAL-AA Phase 2a clinical trial. This is a significant corporate catalyst for Q…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.